

Oncogenic osteomalacia in a patient with an ethmoid sinus tumour

R KURIEN, M T MANIPADAM*, V RUPA

Abstract

Objective: To highlight the clinical presentation and management of a rare case of oncogenic osteomalacia due to an ethmoid sinus tumour.

Materials and methods: We examined the case records of a 55-year-old man who presented with progressive fatigue, weakness and bone pain, and noted the clinical presentation, laboratory investigations, computed tomography findings, operative notes and follow-up details.

Conclusion: Oncogenic osteomalacia secondary to a paranasal sinus neoplasm is a rare entity. The causative tumour is often occult and may be missed by routine clinical examination. This case report illustrates the appropriate pattern of evaluation and management to ensure a successful outcome.

Key words: Osteomalacia; Paranasal Sinus Neoplasms; Ethmoid Sinuses

Introduction

Oncogenic osteomalacia is a rare syndrome characterised by the presence of osteomalacia secondary to a mesenchymal tumour which produces renal phosphate wasting and altered vitamin D metabolism. Most cases of oncogenic osteomalacia are caused by what is currently referred to as 'phosphaturic mesenchymal tumour mixed connective tissue variant'.¹ The hallmark of these tumours is overexpression of fibroblast growth factor 23,² a polypeptide hormone of the fibroblast growth factor family which suppresses phosphate reabsorption and 1,25-dihydroxyvitamin D₃ synthesis. This eventually results in osteomalacia due to phosphaturia, hypophosphataemia, inappropriately low serum 1,25-dihydroxyvitamin D₃ concentration and increased alkaline phosphatase concentration. The consequence of this is demineralisation and subsequent weakening or fractures of bones.

The causative tumour in oncogenic osteomalacia is usually benign and inconspicuous, and a long interval may thus ensue between symptom presentation and tumour identification. These patients are often misdiagnosed as having nutritional osteomalacia and are treated for prolonged periods without any success. In one study, the period between onset of symptoms and excision of the causative tumour was five years.³ Once the tumour is identified and resected, the clinical symptoms and biochemical abnormalities typically disappear. The majority of tumours associated with oncogenic osteomalacia occur in the bone and soft tissue of the upper and lower extremities.^{2,4} Less than one-third of these tumours involve head and neck sites.⁵ Oncogenic osteomalacia caused by tumours of the sphenoidal region is extremely rare. Only six reports of an association with such tumours have been published.^{5–10}

The present report highlights the need for early recognition of the possibility of a sinonasal neoplastic aetiology

for osteomalacia in the elderly. We also emphasise the manner in which detailed head and neck evaluation should be performed in order to detect the causative lesion.

Case report

A 55-year-old man presented complaining of progressive, diffuse muscle and joint pains with difficulty in standing and walking for two years. He had become accustomed to mobilising with a wheelchair. He did not have any ear, nose or throat complaints. He was referred from the Department of Internal Medicine to the Endocrinology department for evaluation of suspected osteomalacia.

Investigation for causes of osteomalacia revealed that the patient had hypophosphataemia, phosphaturia, decreased serum 1,25-dihydroxyvitamin D₃ concentration and elevated parathyroid hormone concentration. The maximum phosphate transportation rate in the renal proximal tubules (calculated as phosphate tubule maximum divided by glomerular filtration rate) was also low. The serum calcium concentration was normal.

After ruling out causes for primary and secondary phosphaturia, the possibility of a tumour causing the same was considered. Although the patient was asymptomatic, an ENT evaluation was sought to exclude sinonasal involvement. Routine history-taking and ENT examination (including rigid nasal endoscopy and X-ray of the paranasal sinuses) failed to reveal any ENT abnormalities. Clinical examination and radiology of the skeletal system, abdomen and lungs did not reveal any masses. The patient was thus diagnosed with nutritional osteomalacia, and was treated with oral vitamin D and calcium supplements.

The patient was reviewed after three months and found to have no improvement in his symptoms and biochemical abnormalities. Suspicion of an underlying neoplastic

aetiology was heightened by the persistence of these clinical and biochemical abnormalities. Thus, the patient was referred to the ENT department to specifically and conclusively exclude an occult tumour of the paranasal sinuses causing oncogenic osteomalacia.

Once again, clinical examination was normal. However, a contrast-enhanced computed tomography (CT) scan of the paranasal sinuses demonstrated a moderately enhancing mass with central hypodense areas in the right sphenoid region (Figure 1).

The patient underwent endoscopic excision of the mass under hypotensive anaesthesia. Intra-operatively, a mucosa-covered, friable, vascular mass was found involving the right posterior ethmoid and sphenoid sinuses. The histopathological diagnosis was a sinonasal-type haemangiopericytoma with positive immunohistochemical staining for smooth muscle actin and vimentin (Figures 2 and 3) and negative staining for cluster of differentiation 34 (CD34) glycoprotein.

In the immediate post-operative period, as well as a week after surgery, there was substantial improvement in the patient's serum phosphate and 24-hour urinary phosphate levels (Table I).

When the patient returned for follow up three months later, he had no bone pains and no longer required a wheelchair. Repeat testing of serum phosphate and 24-hour urinary phosphate levels showed further improvement (Table I).



FIG. 1

Pre-operative, coronal computed tomography scan showing a moderately enhancing mass with central hypodense area in the right sphenoid sinus.




FIG. 2

Photomicrograph showing whorls and short fascicles of bland spindle cells with eosinophilic cytoplasm (H&E; $\times 200$).

At six-month follow up, repeated contrast-enhanced CT scanning of the paranasal sinuses showed no evidence of any residual lesion in the right sphenoid and posterior ethmoid sinuses (Figure 4). Based on the clinical features, histopathological diagnosis and post-operative course of events, a diagnosis of phosphaturic mesenchymal tumour or haemangiopericytoma causing oncogenic osteomalacia was confirmed.

At most recent follow up, three years after diagnosis, the patient was ambulant with no bone pains and normal serum and urinary phosphate levels.

Discussion

Oncogenic osteomalacia is a rare paraneoplastic syndrome which chiefly involves the extremities.^{2,4} Other sites of involvement include the maxillary sinus,^{2,3,11} buccal vestibule,¹² temporal bone,¹³ lung,¹⁴ subcutaneous tissue,¹⁵ metacarpophalangeal joint¹⁶ and frontal lobe.⁸

Our patient presented to the endocrinology department with complaints of generalised body aches and bone pain. Nutritional osteomalacia was the initial diagnosis at presentation, because of the initially negative ENT investigation. A second ENT consultation was sought in view of




FIG. 3

Photomicrograph showing tumour cells with positive cytoplasmic staining for smooth muscle actin ($\times 400$).

TABLE I

PRE- AND POST-OPERATIVE CHANGES IN BIOCHEMICAL PARAMETERS

Parameters	Pre-op	Post-op	
		Immediate	3 mths
Serum phosphate (mg/dL)	1.7	3.0	4.9
Serum calcium (mg/dL)	8.7	8.7	9.5
24-hr urine phosphate (mg/day)	504	105	206
Alkaline phosphatase (U/l)	383	279	332

Pre-op = pre-operative; post-op = post-operative; mths = months; hr = hour

persistent phosphaturia. The occult nature of the tumour was in accordance with other reported cases in which nasal complaints were absent but sinonasal tumours eventually discovered (Table II).⁵⁻¹⁰

Given the vague symptomatology in patients with this condition, it is imperative in the first instance to perform at least a contrast-enhanced CT scan of the paranasal sinuses. Routine examination by anterior rhinoscopy and rigid nasal endoscopy alone could result in the tumour being missed. In previously reported patients with a focus of tumour in the ethmoid sinus, the neoplasm was detected solely by CT scanning or other radiological tests. Thus, both the endocrinologist and the otolaryngologist must have a high index of suspicion, and should proceed with CT or magnetic resonance imaging¹⁷ even if clinical evaluation is negative. Other reported imaging modalities which may be of use are ¹¹¹In-pentetreotide scanning,^{7,18} octreotide scanning¹⁹ and positron emission tomography.²⁰

Oncogenic osteomalacia is associated with a number of benign bone and soft tissue tumours, such as haemangiopericytoma and giant cell tumour.¹⁹ Weidner and Santa



FIG. 4

Post-operative, coronal computed tomography scan of the paranasal sinuses, showing no residual mass in the sphenoid sinus.

TABLE II
PREVIOUS REPORTS OF TUMOURS OF THE SPHEENOETHMOIDAL REGION ASSOCIATED WITH ONCOGENIC OSTEOMALACIA

Study	Age (y)/sex	Symptoms	Imaging	Tumour site	Histology	Treatment	Outcome
Beech <i>et al.</i> ⁵	42/M	Backache, leg pain	MRI	Ethmoid sinus	Haemangiopericytoma	Endoscopic excision	Cured
Fuentealba <i>et al.</i> ⁶	50/M	Backache, leg pain	MRI	Ethmoid sinus	Haemangiopericytoma	Excision, post-op RT	Cured
Ungari <i>et al.</i> ⁷	24/M	Multiple fractures	MRI	Ethmoid sinus	Haemangiopericytoma	Excision	Cured
Sandhu & Martuza ⁸	46/M	Multiple fractures	¹¹¹ In-pentetreotide scan	Ethmoid sinus, frontal lobe	Haemangiopericytoma	Excision, post-op RT	Cured
Gonzalez-Compta <i>et al.</i> ⁹	69/F	Bone pain, hemiparesis	CT	Frontoethmoid & maxillary sinuses	Mesenchymal tumour	Died before treatment	Died of cerebral bleed
Clunie <i>et al.</i> ¹⁰	60/F	Multiple bone pain	CT	Ethmoid sinus	Haemangiopericytoma	Excision	Died of colon Ca

Y = year; M = male; F = female; MRI = magnetic resonance imaging; CT = computed tomography; post-op RT = post-operative radiotherapy; Ca = carcinoma

Cruz,¹ in their landmark study, reviewed previously reported cases of oncogenic osteomalacia and found that most of the tumours associated with this condition had certain histological features in common. They coined the term phosphaturic mesenchymal tumour mixed connective tissue variant to describe these unique lesions. These tumours are characterised by a distinctive admixture of spindle cells, osteoclast-like giant cells and prominent blood vessels which range from capillary-sized channels to hyalinised, thick-walled and haemangiopericytoma-like vessels. The other distinctive feature of this tumour is its matrix, which ranges from myxoid to myxochondroid with foci of calcification and metaplastic bone.

However, the typical features of phosphaturic mesenchymal tumour mixed connective tissue variant are not seen in sinonasal tumours causing oncogenic osteomalacia. In Folpe and colleagues⁴ meta-analysis of a series of 32 cases of oncogenic osteomalacia, there were two sinonasal tumours, both of which lacked the typical features of phosphaturic mesenchymal tumour mixed connective tissue variant; these two tumours resembled sinonasal-type haemangiopericytoma, with small, myoid-appearing, spindle-shaped cells arranged around blood vessels, as seen in our case. Both these tumours lacked matrix production and osteoclast-type giant cells. Furthermore, these tumours' immunohistochemical profile was similar to that of our case, viz, positive for smooth muscle actin and negative for cluster of differentiation 34 glycoprotein.

Sinonasal-type haemangiopericytomas represent less than 1 per cent of all sinonasal tumours. They are composed of short fascicles of uniform, oval- to spindle-shaped cells arranged around vessels which often show perivascular hyalinisation. Sinonasal-type haemangiopericytomas are invariably positive for vimentin, smooth muscle actin and factor XIIIa.²¹

- **Oncogenic osteomalacia is a rare syndrome characterised by the presence of hypophosphataemic, phosphaturic osteomalacia secondary to a benign mesenchymal tumour**
- **As the tumour is often occult and usually benign, its detection poses a diagnostic challenge**
- **Radiological investigations, particularly contrast-enhanced computed tomography scans of the sinuses, should be undertaken despite negative clinical findings**
- **Surgical excision is the mainstay of treatment**
- **The possibility of a benign sinonasal tumour causing phosphaturic, hypophosphataemic oncogenic osteomalacia should be considered by the treating physician, and should prompt early referral to the otolaryngologist**

Sinonasal haemangiopericytoma causing oncogenic osteomalacia is best treated by wide surgical excision. Long term follow up is required to detect any recurrence, and revision surgery may be needed to achieve complete tumour excision.⁶ Post-operative radiotherapy has been recommended in patients with aggressive tumours, although there is limited published evidence for this. One patient who had a sinonasal tumour with intracranial extension received post-operative radiotherapy because of the presence of dural and brain parenchymal invasion.⁸

Biochemical markers are employed both for diagnosis and for monitoring of tumour activity. In patients with suspected oncogenic osteomalacia, measurement of serum

phosphate, as part of routine biochemical investigation, is of utmost importance to distinguish this condition from other cases of osteomalacia.

Conclusion

A diagnosis of hypophosphataemic, phosphaturic osteomalacia is arrived at by clinical and biochemical evaluation, and warrants a complete search for causes of oncogenic osteomalacia. A detailed ENT evaluation should be performed, which should include (at the very least) a contrast-enhanced CT scan of the paranasal sinuses to exclude an occult tumour. Histological characterisation of the tumour is useful in determining whether it is a phosphaturic mesenchymal tumour mixed connective tissue variant or a sinonasal haemangiopericytoma. Wide surgical excision is the treatment of choice. Following excision of the causative tumour, clinical and biochemical improvement is both immediate and dramatic.

References

- 1 Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. *Cancer* 1987;**59**:1442–54
- 2 Koriyama N, Nishimoto K, Kodama T, Nakazaki M, Kurona Y, Yoshida H *et al*. Oncogenic osteomalacia in a case with a maxillary sinus mesenchymal tumor. *Am J Med Sci* 2006;**332**:142–7
- 3 Weidner N, Bar RS, Weiss D, Strottmann MP. Neoplastic pathology of oncogenic osteomalacia/rickets. *Cancer* 1985;**55**:1691–705
- 4 Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY *et al*. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. *Am J Surg Pathol* 2004;**28**:1–30
- 5 Beech TJ, Rokade A, Gittos N, Johnson AP. A haemangiopericytoma of the ethmoid sinus causing oncogenic osteomalacia: a case report and review of the literature. *Int J Oral Maxillofac Surg* 2007;**36**:956–8
- 6 Fuentelba C, Pinto D, Ballesteros F, Pacheco D, Boettiger O, Soto N *et al*. Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. *J Clin Rheumatol* 2003;**9**:373–9
- 7 Ungari C, Rocchi G, Rinna C, Agrillo A, Lattanzi A, Pagnoni M. Hypophosphaturic mesenchymal tumor of the ethmoid associated with oncogenic osteomalacia. *J Craniofac Surg* 2004;**15**:523–7
- 8 Sandhu FA, Martuza RL. Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: case report. *J Neurooncol* 2000;**46**:241–7
- 9 Gonzalez-Compta X, Mañós-Pujol M, Foglia-Fernandez M, Peral E, Condom E, Claveguera T *et al*. Oncogenic osteomalacia: case report and review of head and neck associated tumours. *J Laryngol Otol* 1998;**112**:389–92
- 10 Clunie GPR, Fox PE, Stamp TCB. Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problems of diagnosis, treatment and long term management. *Rheumatology* 2000;**39**:1415–21
- 11 Weiss D, Bar RS, Weidner N, Wener M, Lee F. Oncogenic osteomalacia: strange tumours in strange places. *Postgrad Med J* 1985;**61**:349–55
- 12 Ahn JM, Kim HJ, Cha CM, Kim J, Yim SG, Kim HJ. Oncogenic osteomalacia: induced by tumor, cured by surgery. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007;**103**:636–41
- 13 Kaylie DM, Jackson CG, Gardner EK. Oncogenic osteomalacia caused by phosphaturic mesenchymal tumor of the temporal bone. *Otolaryngol Head Neck Surg* 2006;**135**:653–4
- 14 Schapira D, Ben Izhak O, Nachtigal A, Burstein A, Shalom RB, Shagrawi I *et al*. Tumor-induced osteomalacia. *Semin Arthritis Rheum* 1995;**25**:35–46
- 15 Oka M, Kamo T, Sasaki E, Kaji H, Nishizawa H, Imanishi Y *et al*. A case of phosphaturic mesenchymal tumour (mixed connective tissue variant) that developed in the

- subcutaneous tissue of a patient with oncogenic osteomalacia and produced fibroblast growth factor 23. *Br J Dermatol* 2007;**157**:198–200
- 16 Jacob JJ, Finny P, Thomas M, Thomas N, John M. Oncogenic osteomalacia. *J Assoc Physicians India* 2007;**55**:231–3
- 17 Nelson AE, Mason RS, Robinson BG, Hogan JJ, Martin EA, Ahlström H *et al.* Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. *Eur J Endocrinol* 2001;**145**:469–76
- 18 Casari S, Rossi V, Varenna M, Gasparini M, Parafioriti A, Failoni S *et al.* A case of oncogenic osteomalacia detected by 111 In- pentetreotide total body scan. *Clin Exp Rheumatol* 2003;**21**:493–6
- 19 Harish S, Jurriaans E, Jan E, Sur M, Colterjohn N. Giant cell tumour of soft tissue causing oncogenic osteomalacia: report demonstrating the use of octreotide scintigraphy in tumour localization. *Clin Radiol* 2008;**63**:101–7
- 20 Chua SC, O'Connor SR, Wong WL, Ganatra RH. Case report: solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT.

- A case report with a review of the radiological literature. *Br J Radiol* 2008;**8**:110–14
- 21 Wenig BM. *Atlas of Head and Neck Pathology: Neoplasms of the Nasal Cavity and Paranasal Sinuses*, 2nd edn. New York: Saunders Elsevier, 2008;97–100

Address for correspondence:

Dr V Rupa,
Department of ENT,
Christian Medical College,
Vellore,
Tamilnadu, India 632004.

Fax: +91 0416 2232035

E-mail: ent3@cmcvellore.ac.in

Dr V Rupa takes responsibility for the integrity of the content of the paper.

Competing interests: None declared
